Asset
Apomorphine hydrochloride
Supernus Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01770145 | phase4 | completed | 2012-12-01 | 2014-04-01 | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) |
| NCT02549573 | phase4 | terminated | 2016-01-01 | 2016-12-01 | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN® |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 021264 | NDA | MDD US OPERATIONS LLC |
| NDA 214056 | NDA | MDD US OPERATIONS LLC A SUB OF SUPERNUS PHARMACEUTICALS INC |
Marketed products (3)
- APOKYN
- APOKYN
- ONAPGO